참고문헌
- Chen L and Flies DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13, 227-242 https://doi.org/10.1038/nri3405
- Cai J, Wang D, Zhang G and Guo X (2019) The role of PD-1/PD-L1 axis in treg development and function: implications for cancer immunotherapy. Onco Targets Ther 12, 8437-8445 https://doi.org/10.2147/OTT.S221340
- Xin Yu J, Hodge JP, Oliva C, Neftelinov ST, HubbardLucey VM and Tang J (2020) Trends in clinical development for PD-1/PD-L1 inhibitors. Nat Rev Drug Discov 19, 163-164 https://doi.org/10.1038/d41573-019-00182-w
- Sun L, Zhang L, Yu J et al (2020) Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep 10, 2083 https://doi.org/10.1038/s41598-020-58674-4
- Azuma T, Yao S, Zhu G, Flies AS, Flies SJ and Chen L (2008) B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111, 3635-3643 https://doi.org/10.1182/blood-2007-11-123141
- Yu W, Hua Y, Qiu H et al (2020) PD-L1 promotes tumor growth and progression by activating WIP and beta-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis 11, 506 https://doi.org/10.1038/s41419-020-2701-z
- Lee S-J, Jang B-C, Lee S-W et al (2006) Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274). FEBS Lett 580, 755-762 https://doi.org/10.1016/j.febslet.2005.12.093
- Cancer Genome Atlas Research Network (2017) Integrated genomic and molecular characterization of cervical cancer. Nature 543, 378-384 https://doi.org/10.1038/nature21386
- Steidl C, Shah SP, Woolcock BW et al (2011) MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471, 377-381 https://doi.org/10.1038/nature09754
- Kataoka K, Shiraishi Y, Takeda Y et al (2016) Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534, 402-406 https://doi.org/10.1038/nature18294
- Wu Y, Zhao T, Jia Z et al (2019) Polymorphism of the programmed death‐ligand 1 gene is associated with its protein expression and prognosis in gastric cancer. J Gastroenterol Hepatol 34, 1201-1207 https://doi.org/10.1111/jgh.14520
- Xiao G, Jin L-L, Liu C-Q et al (2019) EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. J Immunother Cancer 7, 1-15 https://doi.org/10.1186/s40425-018-0484-x
- Nair VS, El Salhat H, Taha RZ, John A, Ali BR and Elkord E (2018) DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin Epigenetics 10, 78 https://doi.org/10.1186/s13148-018-0512-1
- Lu C, Paschall AV, Shi H et al (2017) The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion. J Natl Cancer Inst 109, djw283 https://doi.org/10.1093/jnci/djw283
- Casey SC, Tong L, Li Y et al (2016) MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227-231 https://doi.org/10.1126/science.aac9935
- Song TL, Nairismagi M-L, Laurensia Y et al (2018) Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood 132, 1146-1158
- Ruf M, Moch H and Schraml P (2016) PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer 139, 396-403 https://doi.org/10.1002/ijc.30077
- Noman MZ, Desantis G, Janji B et al (2014) PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211, 781-790 https://doi.org/10.1084/jem.20131916
- Green MR, Rodig S, Juszczynski P et al (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18, 1611-1618 https://doi.org/10.1158/1078-0432.CCR-11-1942
- Liu J, Hamrouni A, Wolowiec D et al (2007) Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110, 296-304
- Stutvoet TS, Kol A, de Vries EG et al (2019) MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells. J Pathol 249, 52-64 https://doi.org/10.1002/path.5280
- Coelho MA, de Carne Trecesson S, Rana S et al (2017) Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity 47, 1083-1099 https://doi.org/10.1016/j.immuni.2017.11.016
- Hong S, Chen N, Fang W et al (2016) Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology 5, e1094598 https://doi.org/10.1080/2162402X.2015.1094598
- van Rensburg HJJ, Azad T, Ling M et al (2018) The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1. Cancer Res 78, 1457-1470 https://doi.org/10.1158/0008-5472.CAN-17-3139
- Chen J, Zhang XD and Proud C (2015) Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice. Sci Signal 8, pe1 https://doi.org/10.1126/scisignal.aac8321
- Thiem A, Hesbacher S, Kneitz H et al (2019) IFN-gammainduced PD-L1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res 38, 1-15 https://doi.org/10.1186/s13046-018-1018-6
- Cortez MA, Ivan C, Valdecanas D et al (2016) PDL1 regulation by p53 via miR-34. J Natl Cancer Inst 108, djv303
- Xu Y-p, Lv L, Liu Y et al (2019) Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. J Clin Invest 129, 4316-4331 https://doi.org/10.1172/JCI129317
- Wu A, Wu Q, Deng Y et al (2019) Loss of VGLL 4 suppresses tumor PD‐L1 expression and immune evasion. EMBO J 38, e99506
- Yan Y, Zheng L, Du Q, Yan B and Geller DA (2020) Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. Cancer Immunol Immunother 69, 891-1903
- Dorand RD, Nthale J, Myers JT et al (2016) Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science 353, 399-403 https://doi.org/10.1126/science.aae0477
- Chen L, Liu S and Tao Y (2020) Regulating tumor suppressor genes: post-translational modifications. Signal Transduct Target Ther 5, 90 https://doi.org/10.1038/s41392-020-0196-9
- Wei S, Wang K, Huang X, Zhao Z and Zhao Z (2019) LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed deathligand 1 axis. Int J Immunopathol Pharmacol 33, 2058738419859699
- Zhao L, Liu Y, Zhang J, Liu Y and Qi Q (2019) LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. Cell Death Dis 10, 1-15 https://doi.org/10.1038/s41419-018-1236-z
- Mineo M, Lyons SM, Zdioruk M et al (2020) Tumor interferon signaling is regulated by a lncRNA INCR1 transcribed from the PD-L1 Locus. Mol Cell 78, 1209-1223
- Li CW, Lim SO, Xia W et al (2016) Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun 7, 12632 https://doi.org/10.1038/ncomms12632
- Chan LC, Li CW, Xia W et al (2019) IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest 129, 3324-3338 https://doi.org/10.1172/JCI126022
- Apriamashvili G, Vredevoogd DW, Krijgsman O et al (2020) Loss of ubiquitin ligase STUB1 amplifies IFNγ-R1/JAK1 signaling and sensitizes tumors to IFNγ. bioRxiv, https://doi.org/10.1101/2020.07.07.191650
- Mezzadra R, Sun C, Jae LT et al (2017) Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549, 106-110 https://doi.org/10.1038/nature23669
- Burr ML, Sparbier CE, Chan Y-C et al (2017) CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549, 101-105 https://doi.org/10.1038/nature23643
- Lim SO, Li CW, Xia W et al (2016) Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30, 925-939 https://doi.org/10.1016/j.ccell.2016.10.010
- Zhang J, Bu X, Wang H et al (2019) Author correction: cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 571, E10 https://doi.org/10.1038/s41586-019-1351-8
- Xu J, Meng Q, Li X et al (2019) Long noncoding RNA MIR17HG promotes colorectal cancer progression via miR17-5p. Cancer Res 79, 4882-4895 https://doi.org/10.1158/0008-5472.can-18-3880
- Zhang M, Wang N, Song P et al (2020) LncRNA GATA3- AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif 53, e12855 https://doi.org/10.1111/cpr.12855
- Gato-Canas M, Zuazo M, Arasanz H et al (2017) PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep 20, 1818-1829 https://doi.org/10.1016/j.celrep.2017.07.075
- Dongre A and Weinberg RA (2019) New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20, 69-84 https://doi.org/10.1038/s41580-018-0080-4
- Cao Y, Zhang L, Kamimura Y et al (2011) B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. Cancer Res 71, 1235-1243 https://doi.org/10.1158/0008-5472.CAN-10-2217
- Wang Y, Wang H, Zhao Q, Xia Y, Hu X and Guo J (2015) PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. Med Oncol 32, 212 https://doi.org/10.1007/s12032-015-0655-2
- Qiu XY, Hu DX, Chen WQ et al (2018) PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim Biophys Acta Mol Basis Dis 1864, 1754-1769 https://doi.org/10.1016/j.bbadis.2018.03.002
- Cui P, Jing P, Liu X and Xu W (2020) Prognostic significance of PD-L1 expression and its tumor-intrinsic functions in hypopharyngeal squamous cell carcinoma. Cancer Manag Res 12, 5893-5902 https://doi.org/10.2147/CMAR.S257299
- Fei Z, Deng Z, Zhou L, Li K, Xia X and Xie R (2019) PD-L1 induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells through activation of the PI3K/AKT Pathway. Oncol Res 27, 801-807 https://doi.org/10.3727/096504018X15446984186056
- Zhang Y, Zeng Y, Liu T et al (2019) The canonical TGF-beta/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer. Respir Res 20, 164 https://doi.org/10.1186/s12931-019-1137-4
- Clark CA, Gupta HB, Sareddy G et al (2016) Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res 76, 6964-6974 https://doi.org/10.1158/0008-5472.CAN-16-0258
- Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F and Lisanti MP (2017) Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol 14, 11-31 https://doi.org/10.1038/nrclinonc.2016.60
- Chang CH, Qiu J, O'Sullivan D et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229-1241 https://doi.org/10.1016/j.cell.2015.08.016
- Wang S, Li J, Xie J et al (2018) Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin beta4/SNAI1/SIRT3 signaling pathway. Oncogene 37, 4164-4180 https://doi.org/10.1038/s41388-018-0252-x
- Kim S, Jang JY, Koh J et al (2019) Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer. J Exp Clin Cancer Res 38, 462 https://doi.org/10.1186/s13046-019-1407-5
- Lin R, Zhang H, Yuan Y et al (2020) Fatty acid oxidation controls CD8(+) tissue-resident memory T-cell survival in gastric adenocarcinoma. Cancer Immunol Res 8, 479-492 https://doi.org/10.1158/2326-6066.cir-19-0702
- Najafi M, Farhood B and Mortezaee K (2019) Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol 234, 8381-8395 https://doi.org/10.1002/jcp.27740
- Tamai K, Nakamura M, Mizuma M et al (2014) Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma. Cancer Sci 105, 667-674 https://doi.org/10.1111/cas.12406
- Jinesh GG, Manyam GC, Mmeje CO, Baggerly KA and Kamat AM (2017) Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Sci Rep 7, 9602 https://doi.org/10.1038/s41598-017-08796-z
- Wu Y, Chen M, Wu P, Chen C, Xu ZP and Gu W (2017) Increased PD-L1 expression in breast and colon cancer stem cells. Clin Exp Pharmacol Physiol 44, 602-604 https://doi.org/10.1111/1440-1681.12732
- Almozyan S, Colak D, Mansour F et al (2017) PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation. Int J Cancer 141, 1402-1412 https://doi.org/10.1002/ijc.30834
- Zhang X, Li F, Zheng Y et al (2019) Propofol reduced mammosphere formation of breast cancer stem cells via PD-L1/Nanog in vitro. Oxid Med Cell Longev 2019, 9078209 https://doi.org/10.1155/2019/9078209
- Wei F, Zhang T, Deng SC et al (2019) PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. Cancer Lett 450, 1-13 https://doi.org/10.1016/j.canlet.2019.02.022
- Ishibashi M, Tamura H, Sunakawa M et al (2016) Myeloma drug resistance induced by binding of myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunol Res 4, 779-788 https://doi.org/10.1158/2326-6066.CIR-15-0296
- Black M, Barsoum IB, Truesdell P et al (2016) Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget 7, 10557-10567 https://doi.org/10.18632/oncotarget.7235
- Liu S, Chen S, Yuan W et al (2017) PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways. Oncotarget 8, 99901-99912 https://doi.org/10.18632/oncotarget.21914
- Feng D, Qin B, Pal K et al (2019) BRAF(V600E)-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene 38, 6752-6766 https://doi.org/10.1038/s41388-019-0919-y
- Tu X, Qin B, Zhang Y et al (2019) PD-L1 (B7-H1) Competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy. Mol Cell 74, 1215-1226 e1214 https://doi.org/10.1016/j.molcel.2019.04.005
- Brech A, Ahlquist T, Lothe RA and Stenmark H (2009) Autophagy in tumour suppression and promotion. Mol Oncol 3, 366-375 https://doi.org/10.1016/j.molonc.2009.05.007
- Clark CA, Gupta HB and Curiel TJ (2017) Tumor cell-intrinsic CD274/PD-L1: a novel metabolic balancing act with clinical potential. Autophagy 13, 987-988 https://doi.org/10.1080/15548627.2017.1280223
- Chen RQ, Xu XH, Liu F et al (2019) The binding of PD-L1 and Akt facilitates glioma cell invasion upon starvation via Akt/Autophagy/F-Actin signaling. Front Oncol 9, 1347 https://doi.org/10.3389/fonc.2019.01347
- Gao H, Zhang J and Ren X (2019) PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling. Biosci Rep 39, BSR20191041 https://doi.org/10.1042/BSR20191041
- Huttlin EL, Ting L, Bruckner RJ et al (2015) The BioPlex network: a systematic exploration of the human interactome. Cell 162, 425-440 https://doi.org/10.1016/j.cell.2015.06.043
- Escors D, Gato-Canas M, Zuazo M et al (2018) The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther 3, 26 https://doi.org/10.1038/s41392-018-0022-9